abuse potential
Tris Pharma Achieves Significant Milestone with Non-Opioid Painkiller Cebranopadol in Phase III Trials
Non-opioid pain medication, Cebranopadol, Tris Pharma, Phase III trials, Pain management, Reduced abuse potential, Dual-NMR agonist